What was known before {#section20-2054358117719028}
=====================

In patients with stage 3 and 4 chronic kidney disease (CKD), there is an improvement in brachial blood pressures post renal denervation (RDN). However, no published studies have examined the improvement in central blood pressure post RDN in patients with CKD.

What this adds {#section21-2054358117719028}
==============

At the conclusion of our study we will report the effects of RDN on central blood pressure and arterial stiffness, specifically in patients with resistant hypertension and G3 and G4 CKD.

Introduction {#section22-2054358117719028}
============

It has been shown that lowering of brachial blood pressure (BP) represents a surrogate endpoint that does not automatically lead to a parallel decrease in cardiovascular morbidity and mortality.^[@bibr1-2054358117719028]^ Systolic BP varies across the arterial tree, and counterintuitively, central or aortic systolic pressures are lower than corresponding brachial values. While BP measured over the brachial artery is determined by cardiac output and peripheral vascular resistance, aortic (central) pressures are additionally determined by the stiffness of the conduit vessels and the timing/magnitude of pressure wave reflections.^[@bibr2-2054358117719028][@bibr3-2054358117719028]-[@bibr4-2054358117719028]^ The central systolic BP places a direct burden on the left ventricle, and there is now overwhelming evidence that central hemodynamic indexes (which include aortic pressures, pulse pressures, and augmentation index \[AIx\]) are independent predictors of cardiovascular morbidity and mortality and are more closely correlated with cardiovascular risk than brachial pressures.^[@bibr5-2054358117719028][@bibr6-2054358117719028]-[@bibr7-2054358117719028]^ Recent technological advances have led to central hemodynamics being reliably measured noninvasively with relatively inexpensive devices.^[@bibr7-2054358117719028]^

In the Conduit Artery Function Evaluation Study, a central systolic pressure of 125 mm Hg was associated with a 10% to 30% increase in cardiovascular risk compared with 121 mm Hg.^[@bibr8-2054358117719028]^ In patients with chronic kidney disease (CKD), Townsend measured the central systolic and diastolic pressure in 2144 participants of the Chronic Renal Insufficiency Cohort (CRIC) study and the overall mean ± SD was 116 ± 21 and 71 ± 13 mm Hg, respectively.^[@bibr9-2054358117719028]^ The corresponding office systolic and diastolic BPs were 126 ± 23 and 70 ± 13 mm Hg, respectively.^[@bibr9-2054358117719028]^ The mean central systolic BP was 10 mm Hg lower, although the diastolic pressures were similar. The pulse wave velocity (PWV; m/s) in the same cohort was 9.49 ± 3.04 m/s and, when analyzed in diabetics, was marginally higher at 10.56 ± 3.27 m/s.^[@bibr9-2054358117719028]^ Clinical studies have also shown that in addition to central pressures, increased aortic stiffness, as measured via aortic PWV, is an independent marker of cardiovascular risk and a major contributor to mortality in end-stage renal disease (ESRD).^[@bibr10-2054358117719028][@bibr11-2054358117719028]-[@bibr12-2054358117719028]^

Increased sympathetic activity has been found to be associated with essential hypertension,^[@bibr13-2054358117719028]^ obesity-related hypertension,^[@bibr14-2054358117719028]^ and hypertension associated with obstructive sleep apnea.^[@bibr15-2054358117719028]^ There is evidence suggesting that increased afferent sympathetic activation^[@bibr16-2054358117719028]^ is an early event in CKD^[@bibr17-2054358117719028]^ and that various forms of renal damage lead to a heightened sympathetic drive.^[@bibr17-2054358117719028]^ The ensuing efferent response contributes to propagation of hypertension and adverse cardiovascular events.^[@bibr18-2054358117719028]^ Renal denervation (RDN) delivers radiofrequency energy to interrupt the afferent and efferent renal sympathetic nerve signaling and reduces total sympathetic nerve activity, leading to a decrease in BPs^[@bibr19-2054358117719028]^ and improved cardiac outcomes.^[@bibr20-2054358117719028]^

Although reduction in peripheral, ambulatory BPs and renal outcomes in patients with stage 3 and 4 CKD post RDN has been published,^[@bibr21-2054358117719028],[@bibr22-2054358117719028]^ the relationship of central BP and arterial stiffness in patients with CKD before and after RDN has thus far been unexplored, and there is a paucity of relevant data in the literature. In our single-center prospective study, we aim to follow 50 patients with stage 3 and 4 CKD for 2 years post RDN and to chronologically document changes in central BPs, PWV, peripheral BPs (office and ambulatory), renal biochemical parameters (estimated glomerular filtration rate \[eGFR\] and 24-hour urine for protein), and fasting glucose and insulin levels as well as the change in the dose and number of medications.

Methods {#section23-2054358117719028}
=======

Study Design and Patients {#section24-2054358117719028}
-------------------------

This study is being conducted under a 2-year prospective preintervention/postintervention design. Fifty consecutive stage 3 and 4 CKD patients with resistant hypertension from the Regina Qu'Appelle Health Region multidisciplinary CKD clinic who agree to undergo RDN will be included in the study. Patients are considered eligible if they are older than 18 years and exhibit a systolic BP of greater than 140 mm Hg despite maximal doses of 3 agents (1 of which is a diuretic). Exclusion criteria are documented in [Table 1](#table1-2054358117719028){ref-type="table"}. Once identified as having resistant hypertension based on chart review, the patients undergo evaluation for eligibility to participate in the study ([Figure 1](#fig1-2054358117719028){ref-type="fig"}). Our Research Ethics Board (Institutional Review Board) granted approval for the study (REB-12-73). Patients on clonidine and other sympatholytic agents will not be excluded from the study.

###### 

Exclusion Criteria.

![](10.1177_2054358117719028-table1)

  -------------------------------------------------------------------------------------
  **Exclusion criteria:**\
  Functional adrenal adenoma\
  Renal artery length (on either side) of \<20 mm and diameter of \<4 mm\
  Pregnant or planning pregnancy during the study period\
  Moderate to severe aortic stenosis\
  Cardiac event necessitating introduction of clopidogrel during the prior 12 months\
  Current warfarin use\
  History of cerebrovascular acccident (CVA) 6 months prior to the procedure

  -------------------------------------------------------------------------------------

![Study flowchart.\
*Note.* CKD = chronic kidney disease; CT = computed tomography; TSH = thyroid stimulating hormone; ECHO = echocardiogram.](10.1177_2054358117719028-fig1){#fig1-2054358117719028}

Demographic Information {#section25-2054358117719028}
-----------------------

During the same clinic visit, the patient's age, height, weight, waist circumference, race, gender, current medications being taken, and current medical conditions (peripheral artery disease, diabetes mellitus, coronary heart disease, cerebrovascular disease) are recorded. A quality-of-life questionnaire (EuroQol Five Dimensions Questionnaire \[EQ-5D\], a short standardized instrument to measure health-related quality of life) is also administered, which is to be completed prior to the procedure.

Laboratory Measures {#section26-2054358117719028}
-------------------

The patient receives a requisition to have blood taken at a laboratory within 1 month prior to the RDN procedure to measure the following parameters: serum fasting glucose and insulin, a fasting lipid panel, eGFR, electrolytes, osmolality, complete blood count, and 24-hour urine for sodium, protein, creatinine clearance, potassium, osmolality, and the albumin/creatinine ratio.

Procedure {#section27-2054358117719028}
---------

During renal nerve ablation, a catheter connected to a Medtronic (Santa Rosa, CA, USA) radiofrequency generator is inserted percutaneously through the groin via the femoral artery and advanced up the aorta to the renal arteries. A total of 4 to 6 discrete radiofrequency ablations lasting up to 2 minutes, of 8 watts or less each, are performed, separated both longitudinally and rotationally within each renal artery. The catheter system monitors tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm. The procedure takes approximately 40 minutes to complete the ablations bilaterally. The patient receives intravenous opiates and sublingual anxiolytics, as per the institutional protocol, to reduce visceral pain as well as 3000 IU of intra-arterial heparin in each renal artery prior to the ablations. Post procedure, the patient is monitored in the ambulatory care unit for 4 hours.

The procedure time and contrast volume are documented. The number of successful ablations in each renal artery is also recorded. All adverse events and complications are recorded during each study visit. Specific intervention-related safety data include bleeding or a femoral pseudoaneurysm requiring intervention, renal artery dissection, myocardial infarction, stroke, and death.

Follow-up Schedule {#section28-2054358117719028}
------------------

Seven days after the ablation procedure, the patient receives a phone call from the study coordinator to assess his or her clinical condition. Following appropriate orientation to home BP monitoring, he or she is encouraged to continue to check his or her BP routinely at home (2 times/wk) and inform the attending physician whether his or her BP falls below 100 mm Hg systolic or remains higher than 180/90 mm Hg.

At 3, 6, 12, 18, and 24 months after the procedure (within ±1 month), the study coordinators perform/request the tests documented in [Table 2](#table2-2054358117719028){ref-type="table"}. The patient also undergoes an echocardiogram to examine cardiac function at 12 and 24 months (within ±2 months). The insulin sensitivity index is calculated from fasting glucose and insulin values as follows: homeostatic model assessment--insulin resistance (HOMA-IR) (FPG_FPI), where FPG and FPI are fasting plasma glucose and fasting plasma insulin, respectively.

###### 

List of Investigations at Baseline and at Follow-ups.
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  ---------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient demographics               Age, sex, weight, height, waist circumference, and medication review\
                                     (Baseline and 3, 6, 12, 18, and 24 months)

  Laboratory investigations: blood   Serum urea, creatinine, electrolytes, complete blood count (CBC), fasting panel (glucose, insulin, and lipids), serum osmolality, and HbA1c\
                                     (Baseline and 3, 6, 12, 18, and 24 months)

  Laboratory investigations: urine   Early morning spot urine (for sodium, potassium, osmolality, and the albumin/creatinine ratio) and 24-hour urine (for protein)\
                                     (Baseline and 3, 6, 12, 18, and 24 months)

  Blood pressure                     24-hour ambulatory pressure and office blood pressure (average of 6 readings on BP Tru), central blood pressure (augmentation index \[%\], augmentation pressure \[mm Hg\], central pulse pressure \[mm Hg\], central systolic pressure \[mm Hg\], central diastolic pressure \[mm Hg\], pulse pressure amplification \[mm Hg\], and time to reflection \[Tr\] in ms), and pulse wave velocity\
                                     (Baseline and 3, 6, 12, 18, and 24 months)

  ECHO                               Left ventricle volume, left ventricle hypertrophy, left ventricle function, left atrial mass, E-wave velocity, and E-prime velocity\
                                     (Baseline and 12 and 24 months)
  ---------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Note.* ECHO = echocardiogram.

### Ambulatory BPs and office BPs {#section29-2054358117719028}

Patients will undergo 24-hour BP monitoring (Welch Allyn, Skaneateles Falls, New York), and the following information will be documented: 12-hour daytime systolic pressure (mm Hg), 12-hour daytime diastolic pressure (mm Hg), 12-hour nighttime systolic pressure (mm Hg), and 12-hour nighttime diastolic pressure (mm Hg). The following day, the patients will have the 24-hour arm cuff removed, and they will sit in a quiet room for 10 minutes before the study coordinator can take further peripheral BP measurements using BP Tru (BPM-100, BPTru Medical Devices, Coquitlam, British Columbia, Canada) on the nondominant arm, which measures 6 consecutive BPs (the first is excluded, and the average of the last 5 readings will be documented).

### Central BP {#section30-2054358117719028}

After obtaining the mean of the 5 BP readings, radial artery waveforms will be recorded with a high-fidelity micromanometer from the wrist of the dominant arm and calibrated to the previously measured mean of 5 BP readings. Waveforms will be processed with dedicated software (SphygmoCor CPV \[EM3\] software version 9; AtCor Medical, Inc., Itasca, IL, USA). The integral system software will be used to calculate an average radial artery waveform and to derive a corresponding central aortic pressure waveform using a previously validated generalized transfer function.^[@bibr23-2054358117719028],[@bibr24-2054358117719028]^ Aortic waveforms will be subject to further analysis using the SphygmoCor software to identify the time to the peak/shoulder of the first and second pressure wave components (T1, T2) during systole. The pressure at the peak/shoulder of the first component will be identified as the P1 height, and the pressure difference between this point and the maximal pressure during systole (ΔP, or augmentation) will be identified as the reflected wave during systole. The AIx, defined as the ratio of augmentation to the central pulse pressure (CPP), is expressed as a percentage: AIx = (ΔP / PP) × 100, where P is pressure and PP is pulse pressure. Pulse pressure amplification (PPA) is expressed as the ratio of CPP to brachial pulse pressure (PPP): PPA = PPP / CPP. At least 2 consecutive radial pressure wave samplings will be recorded for each patient, and the mean will be used for analysis. The collected data will include the AIx (%), augmentation pressure (mm Hg), CPP (mm Hg), central systolic pressure (mm Hg), central diastolic pressure (mm Hg), PPA (mm Hg), time to reflection (Tr) in milliseconds, and PWV.

### Pulse wave velocity {#section31-2054358117719028}

The carotid to femoral pulse wave velocity (CF-PWV) will be measured in all patients during every clinic visit. PWV will be determined immediately after the central BPs. This parameter is determined by simultaneous measurement of arterial pressure waves at the carotid and femoral arteries with a pressure transducer. The surface distance from the suprasternal notch to the distal (femoral) recording site will be measured, and the pressure wave transit time will be calculated by dividing the distance to the distal site by the pressure wave transit time. The data are collected by a single trained coordinator (R.J.), and the mean of 2 PWV measurements will be taken for each patient.

Echocardiogram {#section32-2054358117719028}
--------------

The following parameters will be documented: left ventricle volume, left ventricle hypertrophy, left ventricle function, left atrial mass, E-wave velocity, and E-prime velocity.

Endpoints {#section33-2054358117719028}
---------

The primary outcome of interest is the change in central BP from baseline to 6 months post RDN. The secondary outcomes of interest include the change in central BP from baseline to 3, 12, 18, and 24 months post RDN as well as changes in 24-hour peripheral BP, PWV, cardiac parameters, renal biochemical parameters, fasting insulin and glucose levels, and the number of medications.

Sample Size Considerations {#section34-2054358117719028}
--------------------------

With a 1-sided type 1 error rate of 5%, a sample of 50 subjects will provide 90% power to detect a 10/5 mm Hg change in systolic/diastolic central pressures from baseline with a standard deviation of 23/12, which would be clinically significant.

Statistical Analyses {#section35-2054358117719028}
--------------------

Baseline data will be summarized descriptively. The primary outcome will be evaluated using a 1-sided paired samples *t* test for normally distributed data or Mann-Whitney *U* test for nonnormally distributed data. Secondary outcomes will be examined using repeated-measures or mixed-model analyses of variance with correction for multiple comparisons (continuous outcomes), chi-square test (categorical outcomes) for normally distributed data, and Friedman test (continuous) or McNemar test (categorical) for nonnormally distributed data and 2-sided alpha set to .05. Multiple linear regression may be used to account for potential covariates such as age, body mass index, gender, or comorbidities on changes in BP, cardiac or renal parameters, and insulin/glucose.

Results {#section36-2054358117719028}
=======

To date, 26 subjects have been enrolled into the trial. Interim findings are reported. Demographic data are provided in [Table 3](#table3-2054358117719028){ref-type="table"} and medications in [Table 4](#table4-2054358117719028){ref-type="table"}. The number of antihypertensives by CKD stages is provided in [Table 5](#table5-2054358117719028){ref-type="table"}.

###### 

Demographic Data and Results of Baseline Parameters (N = 26).
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  Baseline characteristics            n    Mean         SD
  ----------------------------------- ---- ------------ -----------
  Age, y                              26   62.9         12.2
  Height, cm                          26   173.0        9.4
  Weight, kg                          26   100.8        22.5
  BMI                                 26   33.5         6.0
  Waist circumference, cm             24   114.6        14.6
  Office BP Tru, mm Hg                26   154.5/77.7   13.9/15.5
  Ambulatory 12 h day, mm Hg          26   151.9/70.6   15.5/13.0
  Ambulatory 12 h night, mm Hg        26   140.1/64.8   14.9/12.6
  Central blood pressure, mm Hg       25   128.6/78.1   22.3/15.6
  Augmentation pressure, mm Hg        25   12.5         11.5
  Central pulse pressure, mm Hg       25   52.0         25.6
  Pulse wave velocity, m/s            21   15.7         13.4
  24-h urine protein, g/day           24   1.4          2.0
  Creatinine, µmol/L                  26   176.5        65.4
  Albumin/creatinine ratio, mg/mmol   25   97.3         156.2
  eGFR (MDRD, mL/min per 1.73 m^2^)   26   37.0         12.3
  Urea, mmol/L                        26   12.8         6.8
  Fasting insulin, pmol/L             13   175.8        131.3
  Fasting glucose, mmol/L             23   7.7          2.9
  End diastolic volume, mL/m^2^       26   108.2        24.6
  End systolic volume, mL/m^2^        24   40.6         15.9
  Left atrial volume, mL/m^2^         24   96.3         30.5
  Hypertensive medications, n         26   4.9          1.1
  Stage 3 CKD                         18                
  Stage 4 CKD                         8                 

*Note.* BMI = body mass index; eGFR = estimated glomerular filtration rate; MDRD = modified diet in renal disease; CKD = chronic kidney disease.

###### 

Breakdown by Medication Class.
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  Medications                                    Mean dose/d, mg   CKD stage 3 (n = 18)   CKD stage 4 (n = 8)
  ---------------------------------------------- ----------------- ---------------------- ---------------------
  Aldosterone antagonist                                                                  
   Spironolactone                                50                6                      0
  ACE inhibitors                                                                          
   Perindopril                                   8                 7                      4
   Quinapril                                     40                0                      1
   Ramipril                                      10                1                      0
  Angiotensin receptor blockers                                                           
   Irbesartan                                    300               3                      2
   Valsartan                                     320               2                      0
   Candesartan                                   32                1                      3
   Olmesartan                                    40                1                      1
   Telmisartan                                   80                2                      0
   Losartan                                      100               1                      0
  Thiazide diuretics                                                                      
   Indapamide                                    2.5               6                      2
   Hydrochlorothiazide                           37.5              6                      2
   Metolazone                                    2.5               1                      0
  Loop diuretics: furosemide                     40                3                      5
  Beta-blockers                                                                           
   Metoprolol                                    100               7                      3
   Propranolol                                   40                0                      1
  Vasodilators                                                                            
   Minoxidil                                     7.5               4                      0
   Hydralazine                                   400               5                      5
  Dihydropyridine Ca^2+^ blockers                                                         
   Nifedipine                                    90                4                      0
   Amlodipine                                    10                9                      5
  Nondihydropyridine Ca^2+^ blocker: diltiazem   360               1                      2
  Alpha blocker                                                                           
   Doxazosin                                     16                7                      1
  Centrally acting medications                                                            
   Clonidine                                     0.6               5                      3
   Alpha methyldopa                              750               0                      2

*Note.* CKD = chronic kidney disease; ACE = angiotensin converting enzyme.

###### 

Number of Medications by CKD Stage at Baseline.
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  Number of medications   Stage 3 CKD (n = 18)   Stage 4 CKD (n = 8)
  ----------------------- ---------------------- ---------------------
  4                       10                     3
  5                       5                      2
  6                       2                      1
  7                       1                      1
  8                       0                      1

*Note.* CKD = chronic kidney disease.

Discussion {#section37-2054358117719028}
==========

In CKD, stimulation of renal afferent nerves by various mechanisms, including ischemia and uremic toxins, increases the systemic sympathetic outflow via central integrative pathways in the hypothalamus.^[@bibr25-2054358117719028]^ Targeting renal sympathetic nerves in patients with CKD via luminal delivery of radiofrequency energy therefore appears to be a valid therapeutic option for blocking the cycle between renal sympathetic nervous hyperactivity and deterioration of kidney function.^[@bibr25-2054358117719028]^

Sympathetic denervation by thoracic and lumbar sympathectomy improved BPs and long-term outcomes and supported the physiological basis for RDN.^[@bibr26-2054358117719028]^ On the contrary, the results of percutaneous catheter--based denervation in patients without CKD have been less definitive.^[@bibr27-2054358117719028][@bibr28-2054358117719028][@bibr29-2054358117719028]-[@bibr30-2054358117719028]^ While Symplicity HTN-1 and HTN-2 showed superiority of RDN, the results of Symplicity HTN-3 and the Oslo RDN trial showed no advantage of RDN in BP control. In CKD patients, smaller observational studies by Ott et al^[@bibr22-2054358117719028]^ (n = 27) and Hering et al^[@bibr31-2054358117719028]^ (n = 15) have shown benefit with office BP and improvement in GFR post procedure. This is the first study to our knowledge to evaluate central pressures post RDN. This study aims to address the knowledge gap that exists regarding differential central and brachial pressures post RDN and will provide commentary on the stiffness of the conduit vessels.

The main focus of our study is to determine the differential change between central and peripheral BPs at 6 months and at different intervals for 2 years. From a pathophysiological viewpoint, it is the aortic and not the brachial pressure that is "seen" by the heart and the coronary and cerebral arteries, which are the 3 specific sites where the main clinical events occur.^[@bibr6-2054358117719028]^ It is the aortic systolic pressure that the left ventricle encounters during systole (afterload). Furthermore, the aortic pressure during diastole is a determinant of coronary perfusion. The technique for measuring the aortic central BP noninvasively via radial tonometry, along with the synthesis of an aortic pressure waveform, is reproducible,^[@bibr32-2054358117719028]^ validated,^[@bibr14-2054358117719028],[@bibr17-2054358117719028]^ and is regarded as a reference standard.^[@bibr33-2054358117719028]^ However, it requires additional time and a basic level of operator skill.^[@bibr34-2054358117719028]^ Several epidemiological studies have shown that tonometry-derived central BP is superior to brachial pressures in predicting cardiovascular outcomes.^[@bibr35-2054358117719028][@bibr36-2054358117719028]-[@bibr37-2054358117719028]^

Further to central pressures, we intend to measure pulse wave velocities at baseline and at different time points post RDN, as arterial stiffness has been associated with adverse clinical outcomes. Townsend^[@bibr9-2054358117719028]^ recently published data from the CRIC study that demonstrated that among patients with CKD, CF-PWV is much greater (approximately 2 m/s higher) in the presence of diabetes and increases in tandem with the reduction of GFR (with each 10 mL/min per 1.73 m^2^ decline in GFR being independently associated with an approximate 0.23-m/s increase in CF-PWV). It was therefore no surprise that higher CF-PWVs were associated with faster progression of renal dysfunction. CF-PWV was also independently correlated with 24-hour protein excretion, particularly among participants with diabetes. The impact of PWV post RDN and its relationship with tonometrically derived central BPs have not yet been studied across the spectrum of CKD. We intend to address this knowledge gap.

Finally, we intend to assess the relationship between cardiac parameters and RDN. Left ventricular hypertrophy (LVH) and cardiac fibrosis are consequences of structural impairment of the left ventricle and are associated with cardiovascular morbidity and mortality.^[@bibr38-2054358117719028],[@bibr39-2054358117719028]^ CKD and hypertension both independently increase the risk of heart failure.^[@bibr40-2054358117719028],[@bibr41-2054358117719028]^ Rationally, regression of LVH has been shown to improve cardiovascular outcomes, independent of other risk factors.^[@bibr1-2054358117719028],[@bibr42-2054358117719028]^ There is a paucity of studies addressing the impact of RDN on left ventricular mass in patients with CKD. We intend to address this gap. A detailed analysis of cardiac parameters will also be undertaken. We also intend to add to the existing literature regarding renal outcomes specifically, as well as glucose metabolism.

We expect to see a selective improvement in central BPs, in relation to the peripheral and ambulatory BPs. We hope to see stabilization in eGFR and a reduction in proteinuria.

The limitations of the study include lack of a control group, regression to mean of the treatment group, and given the small sample size, loss of patients to follow-up might influence the readings. Furthermore, we will not have the required technology to measure decrease in the renal sympathetic nerve activity by measuring renal norepinephrine spillover. The last limitation is critical, as with the first-generation catheters, the extent of circumferential ablation has been difficult to determine and suboptimal denervation has been reported.

This study is, to the best of our knowledge, the first to include a measure of central BP to assess the efficacy of RDN in controlling BP in patients with stage 3 and 4 CKD. Furthermore, it will contribute to the limited literature about the impact of RDN on LVH and will provide evidence for the relationship between PWV and central BP post RDN.

If we were to identify a relative decline in central BPs in comparison with brachial pressures, we hope it sets the stage for larger randomized controlled trials.
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